Type-1 collagen differentially alters -catenin accumulation in primary dupuytren's disease cord and adjacent palmar fascia cells

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Vi, Linda ^a   Njarlangattil, Anna ^a   Wu, Yan ^a   Gan, Bing Siang ^a,b   O'Gorman, David B ^a,b  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; COLLAGEN TYPE 1; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; CTNNB1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL TYPE; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; MYOFIBROBLAST; PROTEIN DEPLETION; WESTERN BLOTTING; CASE CONTROL STUDY; FASCIA; METABOLISM; PATHOLOGY; TIME;

ACTINS; BETA CATENIN; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE I; DUPUYTREN'S CONTRACTURE; FASCIA; HUMANS; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 68749096085     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-72     Document Type: Article

References (54)

1. Guillaume Dupuytren and finger contractures. KG Gudmundsson T Jonsson R Arngrimsson, Lancet 2003 362 9378 165 168 10.1016/S0140-6736(03)13871-8 12867120 (Pubitemid 36831031)
2. Dupuytren's disease: an overview. JD Saar PC Grothaus, Plast Reconstr Surg 2000 106 1 125 134 quiz 135-126. 10883625
3. Dupuytren's disease. AJ Thurston, J Bone Joint Surg Br 2003 85 4 469 477 10.1302/0301-620X.85B4.14215 12793547 (Pubitemid 36621959)
4. Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren's disease. KG Gudmundsson R Arngrimsson T Jonsson, Scand J Rheumatol 2001 30 1 31 34 10.1080/030097401750065292 11252689 (Pubitemid 32176221)
5. Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence. S Hindocha JK Stanley S Watson A Bayat, J Hand Surg [Am] 2006 31 10 1626 1634 10.1016/j.jhsa.2006.09.006 17145383 (Pubitemid 44834570)
6. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. MA Badalamente LC Hurst VR Hentz, J Hand Surg [Am] 2002 27 5 788 798 10.1053/jhsu.2002.35299 12239666
7. Enzyme injection as nonsurgical treatment of Dupuytren's disease. MA Badalamente LC Hurst, J Hand Surg [Am] 2000 25 4 629 636 10.1053/jhsu.2000.6918 10913202 (Pubitemid 30602565)
8. Percutaneous needle aponeurotomy: complications and results. G Foucher J Medina R Navarro, J Hand Surg [Br] 2003 28 5 427 431 12954251
9. Needle aponeurotomy for Dupuytren's contracture. HS Cheng LK Hung WL Tse PC Ho, J Orthop Surg (Hong Kong) 2008 16 1 88 90 18453667
10. Dupuytren's disease: diagnosis and treatment. TH Trojian SM Chu, Am Fam Physician 2007 76 1 86 89 17668844
11. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture. L Satish WA Laframboise DB O'Gorman S Johnson B Janto BS Gan ME Baratz FZ Hu JC Post GD Ehrlich, BMC Med Genomics 2008 1 10 18433489 10.1186/1755-8794-1-10
12. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. A Qian RA Meals J Rajfer NF Gonzalez-Cadavid, Urology 2004 64 2 399 404 10.1016/j.urology.2004.04.006 15302515 (Pubitemid 39092491)
13. Expression of a Novel Gene, MafB, in Dupuytren's Disease. LC Lee AY Zhang AK Chong H Pham MT Longaker J Chang, J Hand Surg [Am] 2006 31 2 211 218 10.1016/j.jhsa.2005.09.007 16473681 (Pubitemid 43227270)
14. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. S Rehman F Salway JK Stanley WE Ollier P Day A Bayat, J Hand Surg [Am] 2008 33 3 359 372 10.1016/j.jhsa.2007.11. 010 18343292
15. Collagen of Dupuytren's disease. AJ Bailey TJ Sims G Gabbiani S Bazin M LeLous, Clin Sci Mol Med 1977 53 5 499 502 589933
16. Dupuytren's disease in type I diabetic subjects: investigation of biochemical markers of type III and I collagen. PE Arkkila PJ Koskinen IM Kantola T Ronnemaa E Seppanen JS Viikari, Clin Exp Rheumatol 2000 18 2 215 219 10812494
17. Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. S Bazin M Le Lous VC Duance TJ Sims AJ Bailey G Gabbiani G D'Andiran G Pizzolato A Browski C Nicoletis, Eur J Clin Invest 1980 10 1 9 16 10.1111/j.1365-2362.1980.tb00003.x 6768572
18. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. A Berndt H Kosmehl D Katenkamp V Tauchmann, Pathobiology 1994 62 2 55 58 10.1159/000163879 7524526
19. Beta-catenin signaling in fibroproliferative disease. E Bowley DB O'Gorman BS Gan, J Surg Res 2007 138 1 141 150 10.1016/j.jss.2006.07.026 17109886 (Pubitemid 46227458)
20. Superficial fibromatoses are genetically distinct from deep fibromatoses. E Montgomery JH Lee SC Abraham TT Wu, Mod Pathol 2001 14 7 695 701 10.1038/modpathol.3880374 11455002 (Pubitemid 32667214)
21. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). BA Alman C Li ME Pajerski S Diaz-Cano HJ Wolfe, Am J Pathol 1997 151 2 329 334 9250146
22. Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. H Nagase Y Miyoshi A Horii T Aoki GM Petersen B Vogelstein E Maher M Ogawa M Maruyama J Utsunomiya, Hum Mutat 1992 1 6 467 473 10.1002/humu.1380010603 1338764
23. Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors. Y Nakamura I Nishisho KW Kinzler B Vogelstein Y Miyoshi Y Miki H Ando A Horii, Tohoku J Exp Med 1992 168 2 141 147 10.1620/tjem.168.141 1339098
24. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. SC Abraham C Reynolds JH Lee EA Montgomery BL Baisden AM Krasinskas TT Wu, Hum Pathol 2002 33 1 39 46 10.1053/hupa.2002.30196 11823972 (Pubitemid 34112951)
25. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). S Tejpar F Nollet C Li JS Wunder G Michils P dal Cin E Van Cutsem B Bapat F van Roy JJ Cassiman, Oncogene 1999 18 47 6615 6620 10.1038/sj.onc.1203041 10597266
26. The role of transforming growth factor beta in Dupuytren's disease. MA Badalamente SP Sampson LC Hurst A Dowd K Miyasaka, J Hand Surg [Am] 1996 21 2 210 215 10.1016/S0363-5023(96)80102-X 8683048 (Pubitemid 26099450)
27. TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. A Berndt H Kosmehl U Mandel U Gabler X Luo D Celeda L Zardi D Katenkamp, Histochem J 1995 27 12 1014 1020 8789403
28. Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. SS Cheon P Nadesan R Poon BA Alman, Exp Cell Res 2004 293 2 267 274 10.1016/j.yexcr.2003.09.029 14729464 (Pubitemid 38083216)
29. Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. SS Cheon Q Wei A Gurung A Youn T Bright R Poon H Whetstone A Guha BA Alman, Faseb J 2006 20 6 692 701 10.1096/fj.05-4759com 16581977 (Pubitemid 44933313)
30. TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. S Amini Nik RP Ebrahim K Van Dam JJ Cassiman S Tejpar, Exp Cell Res 2007 313 13 2887 2895 10.1016/j.yexcr.2007.05.024 17601559
31. The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. MA Bisson DA McGrouther V Mudera AO Grobbelaar, J Hand Surg [Br] 2003 28 4 351 356 12849947
32. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. VM Varallo BS Gan S Seney DC Ross JH Roth RS Richards RM McFarlane B Alman JC Howard, Oncogene 2003 22 24 3680 3684 10.1038/sj.onc.1206415 12802275 (Pubitemid 36760730)
33. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. JC Howard VM Varallo DC Ross KJ Faber JH Roth S Seney BS Gan, J Surg Res 2004 117 2 232 238 10.1016/j.jss.2004.01.013 15047128 (Pubitemid 38393648)
34. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. JC Howard VM Varallo DC Ross JH Roth KJ Faber B Alman BS Gan, BMC Musculoskelet Disord 2003 4 16 12866952 10.1186/1471-2474-4-16
35. From collagen type I solution to fibers with a helical pattern: a self-assembly phenomenon. C Vidal Bde, C R Acad Sci III 1995 318 8 831 836 7583771
36. Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. M Wong V Mudera, J Hand Surg [Br] 2006 31 5 473 483 16875762
37. Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords. SA Dave DR Banducci WP Graham 3rd GM Allison HP Ehrlich, Exp Mol Pathol 2001 71 2 147 155 10.1006/exmp.2001.2385 11599921 (Pubitemid 32980627)
38. Increased metabolic activity of fibroblasts derived from cords compared with nodule fibroblasts sampling from patients with Dupuytren's contracture. H Seyhan J Kopp S Schultze-Mosgau RE Horch, Plast Reconstr Surg 2006 117 4 1248 1252 10.1097/01.prs.0000204585.97844.7e 16582795 (Pubitemid 44317818)
39. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. B Shih D Wijeratne DJ Armstrong T Lindau P Day A Bayat, J Hand Surg [Am] 2009 34 1 124 136 10.1016/j.jhsa.2008.09.017 19121738
40. Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications. N Rajan J Habermehl MF Cote CJ Doillon D Mantovani, Nat Protoc 2006 1 6 2753 2758 10.1038/nprot.2006. 430 17406532
41. Novel geometries for tissue-engineered tendonous collagen constructs. Y Shi L Rittman I Vesely, Tissue Eng 2006 12 9 2601 2609 10.1089/ten.2006.12.2601 16995793 (Pubitemid 46141282)
42. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. D Brickley-Parsons MJ Glimcher RJ Smith R Albin JP Adams, J Bone Joint Surg [Am] 1981 63 5 787 797 7240301
43. Hierarchical structures in fibrillar collagens. V Ottani D Martini M Franchi A Ruggeri M Raspanti, Micron 2002 33 7-8 587 596 10.1016/S0968-4328(02) 00033-1 12475555 (Pubitemid 35426583)
44. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. RJ Alioto RN Rosier RI Burton JE Puzas, J Hand Surg [Am] 1994 19 3 442 452 10.1016/0363-5023(94)90059-0 8056971
45. Cellular structure and biology of Dupuytren's disease. JJ Tomasek MB Vaughan CJ Haaksma, Hand Clin 1999 15 1 21 34 10050239
46. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. PJ Wipff DB Rifkin JJ Meister B Hinz, J Cell Biol 2007 179 6 1311 1323 18086923 10.1083/jcb.200704042 (Pubitemid 350277747)
47. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. GR Grotendorst H Rahmanie MR Duncan, Faseb J 2004 18 3 469 479 10.1096/fj.03-0699com 15003992 (Pubitemid 38326303)
48. The matrix reorganized: extracellular matrix remodeling and integrin signaling. M Larsen VV Artym JA Green KM Yamada, Curr Opin Cell Biol 2006 18 5 463 471 10.1016/j.ceb.2006.08.009 16919434 (Pubitemid 44332914)
49. Mechanoregulation of gene expression in fibroblasts. JH Wang BP Thampatty JS Lin HJ Im, Gene 2007 391 1-2 1 15 10.1016/j.gene.2007.01.014 17331678 (Pubitemid 46371351)
50. The characterization of alpha5-integrin expression on tubular epithelium during renal injury. LR White JB Blanchette L Ren A Awn K Trpkov DA Muruve, Am J Physiol Renal Physiol 2007 292 2 F567 576 10.1152/ajprenal.00212.2006 17018844 (Pubitemid 46220523)
51. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. G Zambruno PC Marchisio A Marconi C Vaschieri A Melchiori A Giannetti M De Luca, J Cell Biol 1995 129 3 853 865 7537276 10.1083/jcb.129.3.853
52. Immunohistochemical expression and distribution of alpha2beta1, alpha6beta1, alpha5beta1 integrins and their extracellular ligands, type IV collagen, laminin and fibronectin in palmar fibromatosis. G Magro F Fraggetta S Travali S Lanzafame, Gen Diagn Pathol 1997 143 4 203 208 9489951
53. Co-ordinate expression of alpha 5 beta 1 integrin and fibronectin in Dupuytren's disease. G Magro S Lanzafame G Micali, Acta Histochem 1995 97 3 229 233 8525780
54. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. A Koenig C Mueller C Hasel G Adler A Menke, Cancer Res 2006 66 9 4662 4671 10.1158/0008-5472.CAN-05-2804 16651417